当前位置: X-MOL 学术Acta Neuropathol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Acta Neuropathologica ( IF 12.7 ) Pub Date : 2021-09-18 , DOI: 10.1007/s00401-021-02369-1
Philipp Sievers 1, 2 , Damian Stichel 1, 2 , Martin Sill 3, 4 , Daniel Schrimpf 1, 2 , Dominik Sturm 3, 5, 6 , Florian Selt 3, 5, 7 , Jonas Ecker 3, 5, 7 , Daniel Kazdal 8 , Evelina Miele 9 , Mariëtte E G Kranendonk 10 , Bastiaan B J Tops 10 , Patricia Kohlhof-Meinecke 11 , Rudi Beschorner 12 , Christof M Kramm 13 , Martin Hasselblatt 14 , Guido Reifenberger 15, 16 , David Capper 17, 18 , Pieter Wesseling 10, 19 , Albrecht Stenzinger 8 , Till Milde 3, 5, 7 , Andrey Korshunov 1, 2, 3 , Olaf Witt 3, 5, 7 , Stefan M Pfister 3, 4, 5 , Wolfgang Wick 20, 21 , Andreas von Deimling 1, 2 , David T W Jones 3, 6 , Felix Sahm 1, 2, 3
Affiliation  



中文翻译:

GOPC:ROS1 和其他 ROS1 融合体代表了多种神经胶质瘤类型中罕见但反复出现的药物靶点。

更新日期:2021-09-18
down
wechat
bug